Open AccessCompliance, adverse effects and effectiveness of first line bismuth-containing quadruple treatment (Pylera�) to eradicate Helicobacter pylori infection in 200 patients
Author(s) -
Manuel Fernández,
Teresa Romero García,
Alma Keco Huerga,
Manuel Pabón Jaén,
E. Lamas Rojas,
Rocío Llorca Fernández,
Lourdes Grande Santamaría,
M. Feria
Publication year - 2019
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2019.5950/2018
Subject(s) - medicine , metronidazole , adverse effect , helicobacter pylori , gastroenterology , urea breath test , proton pump inhibitor , lansoprazole , surgery , antibiotics , helicobacter pylori infection , microbiology and biotechnology , biology
quadruple therapy with bismuth is recommended as a first line treatment for Helicobacter pylori (H. pylori) infection. The aim of this study was to evaluate the compliance, adverse effects and effectiveness of this treatment with the new galenic three-in-one capsule formulation containing bismuth subcitrate, metronidazole and tetracycline (Pylera®).